2022 Fiscal Year Final Research Report
Innovation of age-related macular disease treatment by a scalable DDS platform
| Project/Area Number |
20K12640
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 90120:Biomaterials-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 薬物送達 / 網膜 / 後眼部 / 加齢黄斑変性症 / 新生血管 / 脈絡膜 |
|---|
| Outline of Final Research Achievements |
The purpose of this study was to develop a drug delivery device that can be easily placed or detached from the posterior segment of the eye, allowing for long-term sustained drug delivery without invasive procedures. Five candidate drugs with different mechanisms of action from conventional VEGF inhibitors were evaluated for their sustained release potential, and one drug that achieved long-term sustained release was selected for evaluation of its anti-angiogenic effect using in vitro cell culture and animal experiments. The results showed that the drug delivery device inhibited the proliferation of endothelial cells in vitro. However, in rat experiments, it was unable to inhibit laser-induced choroidal neovascularization. In rabbit experiments, insufficient drug transfer to the retina was suggested. Therefore, exploring drug release conditions to improve drug transfer to the retina is a future challenge.
|
| Free Research Field |
生体材料学、薬物送達学、眼科学
|
| Academic Significance and Societal Importance of the Research Achievements |
高齢化長寿社会の到来とともに難治性網膜疾患の罹患者は世界的に増加の一途にあり、中でも加齢黄斑変性症は高齢化で将来の失明原因1位が予測されており治療法開発は喫緊の課題である。現状の治療法は眼内に侵襲的で、視力維持には毎月の眼内注射が必要なため通院や高額な医療費など患者への負担は大きい。本研究は眼内に長期間薬剤投与が可能な薬剤徐放デバイスを開発し安全で確実な治療法を開発することを目的とした。その結果、薬物徐放デバイスは完成し細胞培養レベルで有効性を認めたが、動物実験では有効性を得ることができなかった。網膜に薬物が到達するまでのバリアを理解し、薬物放出性の改善をすることが今後の課題である。
|
